Byetta (exenatide)
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 62 (Table of Contents)
Published: 5 Aug-2005
DOI: 10.3833/pdr.v2005.i62.647 ISSN: 1756-7874
Section: Deal Trackers
Fulltext:
Abstract
Exenatide, a glucagon-like peptide-1 (GLP-1) agonist, which has a longer half-life than GLP-1 itself, is a synthetic exendin-4 compound that belongs to a class of diabetes treatments known as incretin mimetics, which work by mimicking the glucose lowering actions of naturally occurring human hormones (such as GLP-1) called incretins...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS